DNTH שווי כולל של נכסי החברה Dianthus Therapeutics Inc

Dianthus Therapeutics (DNTH) is managed by a team of specialized professionals with deep experience in drug discovery and a transparent leadership structure. The business focuses on identifying treatments for autoimmune pathologies, while a lack of sales leaves the company dependent on external financing. Total assets amount to 769.62. The available price action reflects high volatility driven by R&D expenditures and clinical trial risks.

When constructing a defensive portfolio, analyzing the total resources—which this indicator determines inversely via ROA by summing liabilities and equity to assess the actual scale of the business—is critically important. In the case of Dianthus Therapeutics (DNTH), the growth trend of all company resources reflects investments in creating a technological barrier through the development of innovative monoclonal antibodies, confirming the expansion of the material base for combating rare diseases.